Top 25 Companies in Global Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market (2024–2035): Spherical Insights Analysis

Description

According to a research report published by Spherical Insights & Consulting, the Global Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Size is projected to grow from USD 17.09 Billion in 2024 to USD 80.23 Billion by 2035, at a CAGR of 15.09% during the forecast period 2024–2035. The growth of the Non-Alcoholic Fatty Liver Disease (NAFLD) drug market is driven by rising prevalence of obesity and diabetes, increasing awareness, advancements in therapeutics, supportive government initiatives, growing clinical trials, and demand for effective liver disease management solutions.

 

Introduction

The Non-Alcoholic Fatty Liver Disease (NAFLD) drug market refers to the development and commercialization of therapies aimed at treating liver fat accumulation not caused by alcohol consumption, often linked to metabolic disorders. Market growth is driven by the rising prevalence of obesity, diabetes, and sedentary lifestyles, increasing demand for effective pharmacological treatments. These drugs are widely applied in managing liver inflammation, fibrosis, and preventing progression to non-alcoholic steatohepatitis (NASH) and cirrhosis. Government initiatives, including awareness campaigns and funding for liver disease research, are accelerating drug development and early diagnosis programs. Recent developments include late-stage clinical trials and regulatory advancements for novel drug candidates targeting metabolic and inflammatory pathways. News highlights growing partnerships between pharmaceutical companies to accelerate commercialization. Technological advancements such as biomarker-based diagnostics, precision medicine approaches, and AI-driven drug discovery are further enhancing treatment outcomes, making NAFLD therapeutics a rapidly evolving and high-potential healthcare segment globally.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market.

 

Market Segmentation

Global Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Vitamin E & Pioglitazone, FXR Agonists, PPAR Agonists, GLP-1 Receptor Agonists, Others), By Indication (NAFLD, Non-Alcoholic Steatohepatitis (NASH), Liver Fibrosis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Specialty Clinics, Research Institutes), By Region (North America, Europe, Asia Pacific, LAMEA), Analysis and Forecast, 2024–2035.

 

Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Size & Statistics

• The Market Size for Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Was Estimated to be worth USD 17.09 Billion in 2024.
• The Market is Going to Expand at a CAGR of 15.09% between 2024 and 2035.
• The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Size is anticipated to reach USD 80.23 Billion by 2035.
• North America is expected to generate the highest demand during the forecast period in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market
• Asia Pacific is expected to grow the fastest during the forecast period in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market.

 

Regional growth and demand                                     

Asia Pacific is expected to grow the fastest during the forecast period in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug market. The region’s expansion is driven by the rapidly increasing prevalence of obesity, diabetes, and metabolic syndrome, particularly in countries such as China, India, Japan, and South Korea. Rising awareness about liver health, improving healthcare infrastructure, and increasing healthcare expenditure are boosting demand for early diagnosis and treatment. Government initiatives focused on non-communicable disease management and screening programs are supporting market growth. Additionally, the growing availability of cost-effective therapies, expansion of pharmaceutical manufacturing, and increasing clinical research activities are significantly contributing to regional market expansion.

 

North America is expected to generate the highest demand during the forecast period in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug market. Demand is fueled by a high prevalence of lifestyle-related disorders, strong healthcare infrastructure, and advanced diagnostic capabilities. The United States and Canada lead in clinical trials and drug development activities, supported by significant investments in research and development. Government-backed health programs and favorable regulatory frameworks accelerate drug approvals and adoption. Furthermore, increasing awareness among patients and healthcare providers, along with the presence of major pharmaceutical companies and continuous innovation in targeted therapies, is driving sustained market growth in the region.

 

 

Top 10 Trends in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market

• Increasing focus on targeted therapies for NASH and liver fibrosis
  • Rising investment in clinical trials and drug pipeline development
  • Growing adoption of combination therapies for improved efficacy
  • Advancements in biomarker-based diagnosis and treatment monitoring
  • Increasing use of GLP-1 and metabolic-based drugs
  • Expansion of precision medicine approaches in liver disease treatment
  • Strategic collaborations between pharmaceutical and biotech companies
  • Rising demand for non-invasive diagnostic solutions
  • Integration of AI in drug discovery and development
  • Growing emphasis on early-stage disease management and prevention

 

Top 5 Trends

1. Increasing Focus on Targeted Therapies

Pharmaceutical companies are developing drugs targeting specific pathways such as inflammation, fibrosis, and lipid metabolism. These targeted therapies aim to improve treatment outcomes for patients with NAFLD and its advanced stage, NASH.

 

2. Rising Investment in Clinical Trials

There is a significant increase in global clinical trials for NAFLD drugs, driven by the absence of approved therapies. Companies are investing heavily in late-stage pipeline candidates to gain regulatory approvals and market entry.

 

3. Growing Adoption of Combination Therapies

Combination therapies are gaining traction as they address multiple disease mechanisms simultaneously. This approach enhances efficacy and is increasingly preferred for managing complex liver conditions like NASH.

 

4. Advancements in Biomarker-Based Diagnosis

Innovations in biomarkers and non-invasive diagnostic tools are improving early detection and treatment monitoring. This is enabling personalized treatment strategies and reducing dependence on liver biopsies.

 

5. Integration of AI in Drug Development

Artificial intelligence is being widely used to accelerate drug discovery, optimize clinical trials, and identify potential therapeutic targets, significantly reducing time and cost in NAFLD drug development.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market.

 

Top 25 Companies Leading the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market

1. Novo Nordisk A/S
2. Eli Lilly and Company
3. Pfizer Inc.
4. AstraZeneca plc
5. Novartis AG
6. Gilead Sciences, Inc.
7. Intercept Pharmaceuticals, Inc.
8. Madrigal Pharmaceuticals, Inc.
9. Viking Therapeutics, Inc.
10. Galmed Pharmaceuticals Ltd.
11. Genfit S.A.
12. Allergan (AbbVie Inc.)
13. Bristol-Myers Squibb Company
14. Boehringer Ingelheim International GmbH
15. Merck & Co., Inc.
16. Sanofi S.A.
17. Takeda Pharmaceutical Company Limited
18. Roche Holding AG
19. Johnson & Johnson Services, Inc.
20. GlaxoSmithKline plc
21. Regeneron Pharmaceuticals, Inc.
22. Amgen Inc.
23. Zydus Lifesciences Limited
24. Cipla Limited
25. Reddy’s Laboratories Ltd.

 

1. Novo Nordisk A/S

Headquarters: Bagsvaerd, Denmark

Novo Nordisk A/S is a leading player in the NAFLD drug market, leveraging its strong portfolio in metabolic disorders, particularly GLP-1 receptor agonists such as semaglutide. The company focuses on addressing the root causes of NAFLD, including obesity and type 2 diabetes, through innovative therapies. It invests heavily in clinical trials targeting NASH and liver fibrosis, aiming to expand indications for its existing drugs. Novo Nordisk’s strong R&D capabilities, global presence, and strategic collaborations position it at the forefront of the NAFLD therapeutics landscape.

 

2. Eli Lilly and Company

Headquarters: Indianapolis, Indiana, United States

Eli Lilly and Company is a key competitor in the NAFLD drug market, driven by its advancements in metabolic and endocrine therapies. Its GLP-1 and dual agonist drugs, including tirzepatide, are showing promising results in reducing liver fat and improving metabolic health. The company is actively involved in clinical research targeting NASH, with a focus on combination therapies. Strong investment in innovation, a robust pipeline, and strategic partnerships enhance Lilly’s competitive positioning in this rapidly evolving market.

 

3. Pfizer Inc

Headquarters: New York, United States

Pfizer Inc. is actively expanding its presence in the NAFLD drug market through research in anti-inflammatory and metabolic-targeted therapies. The company leverages its global R&D infrastructure and expertise in drug development to explore novel treatment pathways for liver diseases. Pfizer’s involvement in collaborations and licensing agreements strengthens its pipeline for NAFLD and NASH therapeutics. Its global reach, regulatory expertise, and strong commercialization capabilities support its growing role in this segment.

 

4. AstraZeneca pl

Headquarters: Cambridge, United Kingdom

AstraZeneca plc plays a significant role in the NAFLD drug market, focusing on cardiovascular, renal, and metabolic diseases. The company is developing therapies that address metabolic dysfunction associated with NAFLD, including SGLT2 inhibitors and combination treatments. AstraZeneca emphasizes precision medicine and data-driven approaches to improve patient outcomes. Its strong pipeline, continuous innovation, and global clinical trial presence contribute to its expanding footprint in the NAFLD space.

 

5. Novartis AG

Headquarters: Basel, Switzerland

Novartis AG is a prominent participant in the NAFLD drug market, with a focus on advanced therapeutics targeting inflammation and fibrosis. The company is actively engaged in research collaborations and clinical trials aimed at developing effective NASH treatments. Novartis leverages cutting-edge technologies, including gene therapy and AI-driven drug discovery, to accelerate innovation. Its strong global presence, diversified portfolio, and commitment to addressing unmet medical needs position it as a key player in the evolving NAFLD therapeutics market.

 

Are you ready to discover more about the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug market?

The report provides an in-depth analysis of the leading companies operating in the global Non-Alcoholic Fatty Liver Disease (NAFLD) Drug market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Novo Nordisk A/S
   • Business Overview
   • Company Snapshot
   • Products Overview
   • Company Market Share Analysis
   • Company Coverage Portfolio
   • Financial Analysis
   • Recent Developments
   • Merger and Acquisitions
   • SWOT Analysis
2. Eli Lilly and Company
3. Pfizer Inc.
4. AstraZeneca plc
5. Novartis AG
6. Gilead Sciences, Inc.
7. Intercept Pharmaceuticals, Inc.
8. Madrigal Pharmaceuticals, Inc.
9. Viking Therapeutics, Inc.
10. Others.

 

Conclusion

The non-alcoholic fatty liver disease (NAFLD) drug market is poised for significant growth during the forecast period of 2024–2035, driven by the rising global burden of obesity, diabetes, and metabolic disorders. Increasing awareness about liver health, coupled with advancements in diagnostic techniques, is accelerating early detection and treatment adoption. The market is witnessing strong momentum in research and development, with numerous pipeline candidates targeting key pathways such as inflammation, fibrosis, and lipid metabolism. Government support, regulatory encouragement, and growing healthcare investments are further facilitating drug approvals and commercialization. Additionally, the emergence of combination therapies, precision medicine, and AI-driven drug discovery is transforming the treatment landscape. North America leads in terms of innovation and demand, while Asia Pacific is emerging as a high-growth region due to improving healthcare infrastructure and patient awareness. Overall, the market presents substantial opportunities for pharmaceutical companies, with continuous innovation expected to address unmet clinical needs and drive long-term expansion.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter